IMF Videos Search Content For Healthcare Professional (132) Healthcare Provider (132) Care Partner (67) Patient (67) Series - Any - ASCO/EHA (51) ASH (69) Ask Dr. Durie (23) Black Swan Research Initiative (2) Emerging Therapies (3) Facebook Live (6) IMWG (4) Living Well with Myeloma (2) Myeloma in a Minute (5) Myeloma Made Simple (5) Myeloma University (4) Patient & Family Webinar (1) Q&A (11) Recent News and Developments (4) Treatments (1) Trending Searches in Myeloma (1) Topics Clinical Trials (184) Financial Considerations (15) Frontline Therapy (81) Health Equity (33) Inspirational Stories (23) Insurance (6) Lab & Imaging Tests (68) Lifestyle (47) Mental & Emotional Health (28) Myeloma 101 (54) Myeloma in the News (7) Public Policy & Advocacy (17) Q&A's (41) Recorded Seminars & Workshops (14) Recorded Webinars (23) Relapse/Refractory Myeloma (135) Research Updates (192) Symptom Management (113) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (68) High-Risk Myeloma (45) High-risk Smoldering Myeloma (38) Late Relapse (4–6 Lines of Therapy) (84) MGUS (39) Newly Diagnosed (Pre-Treatment or First Treatment) (63) Smoldering Myeloma (49) Types of Therapy Immunomodulatory drugs (IMiDs) (60) Immunotherapies (CAR T; BiTE, etc.) (100) Monoclonal antibodies (54) Proteasome inhibitors (46) Stem cell transplant (38) Steroids (42) Supportive Care (43) Year Published 2026 (20) 2025 (32) 2024 (52) 2023 (43) 2022 (17) 2021 (12) 2020 (1) 2019 (10) 2018 (2) 2017 (1) 2016 (2) Trusted Voices Dr. Joseph Mikhael (36) Dr. Brian GM Durie (20) Dr. María-Victoria Mateos (7) Dr. Saad Usmani (3) Dr. Shaji Kumar (2) Dr. Sigurður Kristinsson (2) Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO (1) Donna Catamero, ANP-BC, OCN, CCRC (1) Dr. Sagar Lonial (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance Prevalence of Smoldering Multiple Myeloma: Results from the iStopMM Study December 15, 2021 ASH High Prevalence of Monoclonal Gammopathy in a Population at Risk: The First Results of the PROMISE Study December 13, 2021 ASH Assessment of Treatment Response By Ife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial December 13, 2021 ASH How important are the four iStopMM abstracts being presented at ASH for myeloma patients? December 8, 2021 Ask Dr. Durie IMF Global Research Collaborations Bring Us Closer to a Cure October 21, 2021 Living Well with Myeloma What is the immune therapy registry being developed by the IMF? August 3, 2021 Ask Dr. Durie What is the “virtual” biobank being developed by the IMF? July 27, 2021 Ask Dr. Durie When patients test as having borderline high-risk smoldering myeloma, should they receive treatment? January 13, 2021 Ask Dr. Durie Analysis of treatment efficacy in the GEM-CESAR trial for high-risk smoldering multiple myeloma patients June 11, 2020 ASCO/EHA La espectrometría de masa Qip en pts con MM de alto riesgo latente incluidos en el ensayo GEM-CESAR December 13, 2019 ASH Estrategia curativa (GEM-CESAR) para el mieloma latente de alto riesgo (SMM) December 11, 2019 ASH Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM) December 11, 2019 ASH Load More
